PRQR:NASDAQProQR Therapeutics N.V. analysis

The moving-average structure behind ProQR Therapeutics N.V. is neutral at $1.35, with no clear ordering between short and long averages. Over a rolling month the price has lost 33.9%. Relative strength is 26.9 — oversold — and the MACD signal is bearish. The recent range runs from support at $1.30 up to resistance at $1.89.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. Consensus targets land 474.0% above where the shares trade now. Revenue is growing at 120.4% on a -228.2% profit margin.
The composite risk read is 9/10, putting it in high territory. With 30-day volatility of 57.0%, a beta of 1.83 and a maximum drawdown of 57.0%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 90 on the fear-greed composite.
Short, medium and long-term reads agree on hold, with conviction of 1/10.